Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 4, 2014, Pages 429-437

  Crowell, Trevor A ^a   Gebo, Kelly A ^a   Balagopal, Ashwin ^a   Fleishman, John A ^b   Agwu, Allison L ^a   Berry, Stephen A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Health care utilization; Hepatitis B; Hepatitis C; HIV; Hospitalizations

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROPATHY; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ICD-9; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL DISEASE; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; SELF REPORT; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898744479     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000059     Document Type: Article

References (40)

1. Thomas DL, Leoutsakas D, Zabransky T, et al. Hepatitis C in HIVinfected individuals: Cure and control, right now. J Int AIDS Soc. 2011;14:22
2. Weber R, Sabin C, Reiss P, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: The D:A:D Cohort Study. Antivir Ther. 2010;15:1077-1086
3. Sollima S, Caramma I, Menzaghi B, et al. Chronic coinfection with hepatitis B and hepatitis C viruses in an Italian population of HIVinfected patients. J Acquir Immune Defic Syndr. 2007;44:606-607
4. Sherman KE, Rouster SD, Chung RT, et al. Virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837
5. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926
6. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol. 2007;47:527-537
7. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIVinfected patients: The French national Mortalite 2005 study. J Hepatol. 2009;50:736-745
8. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med. 2006;166:1632-1641
9. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: Prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165-172
10. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community- based long-term prospective study. J Infect Dis. 2012;206:469-477
11. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369-378
12. Bedimo R, Westfall AO, Mugavero M, et al. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462-468
13. Naing C, Mak JW, Ahmed SI, et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. World J Gastroenterol. 2012;18:1642-1651
14. Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol. 2012;2012: 871401
15. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843-1847
16. Clifford DB, Evans SR, Yang Y, et al. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(suppl 3):S64-S71
17. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: What is the impact of CD4 counts and HAART use J Acquir Immune Defic Syndr. 2010;54:248-257
18. Berry SA, Fleishman JA, Moore RD, et al. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59:368-375
19. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705-2715
20. Moore RD. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002;30:21-26
21. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr. 2003;34:165-173
22. Clinical Classifications Software (CCS), 2013 [computer program]. Rockville, MD: U.S. Agency for Healthcare Research and Quality; 2013
23. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19
24. Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV Infection, 1995-2007: A Danish populationbased, nationwide cohort study. Clin Infect Dis. 2008;47:1345-1353
25. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43:90-98
26. Mussini C, Galli L, Lepri AC, et al. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: Data from the ICONA Foundation cohort. J Acquir Immune Defic Syndr. 2013;63: 339-345
27. King E, Trabue C, Yin D, et al. Hepatitis C: The complications of immune dysfunction. Expert Rev Clin Immunol. 2007;3:145-157
28. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: Facts and controversies. Lancet Infect Dis. 2007;7:804-813
29. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010; 362:812-822
30. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250-1259
31. Hilsabeck RC, Castellon SA, Hinkin CH. Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis. 2005;41 (suppl 1):S38-S44
32. Winiarski MG, Beckett E, Salcedo J. Outcomes of an inner-city HIV mental health programme integrated with primary care and emphasizing cultural responsiveness. AIDS Care. 2005;17:747-756
33. Weaver MR, Conover CJ, Proescholdbell RJ, et al. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J MentHealth Policy Econ. 2009;12:33-46
34. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIVinfected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther. 2010;15:881-886
35. Reiberger T, Obermeier M, Payer BA, et al. Considerable undertreatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther. 2011;16:815-824
36. Vellozzi C, Buchacz K, Baker R, et al. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. J Viral Hepat. 2011;18:316-324
37. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605
38. Thomas DL, Bartlett JG, Peters MG, et al. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis. 2012;54:979-983
39. Thomas DL. Curing hepatitis C with pills: A step toward global control. Lancet. 2010;376:1441-1442
40. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA. 2000;284:450-456